TUBO bearing mice receiving class I or class II pulsed HER2-DC1 vaccine showed significantly delayed tumor growth compared to control mice (Figures 2A,B; p < 0.001) irrespective of whether HER2-DC1 vaccine was given once, twice or three times weekly. This evidence concerns the gene ERBB2 and neoplasm.